All In Biotech

Drug Trial Radar · NCT05352815

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec

A 52 Week Study Comparing the Efficacy and Safety of Once Weekly IcoSema and Once Weekly Insulin Icodec, Both Treatment Arms With or Without Oral Anti Diabetic Drugs, in Participants With Type 2 Diabetes Inadequately Controlled With Daily Basal Insulin.

Last checked: Nov 20, 2026Latest source record: Dec 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,291 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,291

Actual

Start

Jun 1, 2022

Primary completion

Mar 19, 2024

Study completion Apr 23, 2024

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Apr 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin icodec taken once a week in people with type 2 diabetes. The study will look at how well IcoSema controls blood sugar level in people with type 2 diabetes compared to insulin icodec. Participants will either get IcoSema or insulin icodec. Which treatment participants get is decided by chance. IcoSema and insulin icodec are both new medicines that doctors cannot prescribe. Participants will get IcoSema or insulin icodec, which participants must inject once a week with a pen, which has a small needle, in a skin fold in the thigh, upper arm, or stomach. The study will last for about 1 year and 1 month. Participants will have 21 clinic visits, 31 phone/video calls with the study doctor, and 4 contacts with the site that can either be clinic visits or phone/video calls At 11 clinic visits participants will have blood samples taken. At 7 clinic visits participants cannot eat or drink (except for water) for 8 hours before the visit. Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period. Not applicable for China: Participants will be asked to wear a sensor that measures their blood sugar level all the time during a 5 week period at the end of the study.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • IcoSemaDrug

    Participants will receive once weekly IcoSema subcutanously (s.c. under the skin) with or without oral anti diabetic drugs for 52 weeks.

  • Insulin icodecDrug

    Participants will receive once weekly Insulin icodec subcutanously (s.c. under the skin) with or without oral anti diabetic drugs for 52 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Glycated Haemoglobin (HbA1c)Time frame: Baseline (Week 0), Week 52

Locations

281 sites in 22 countries. Site status is shown where the registry gives one.

  • Pri Med Grp dba/Gil Ctr Fam

    Gilbert, Arizona

  • Lenzmeier Fam Med CCT Research

    Glendale, Arizona

  • Phoenician Centers for Research & Innovation PCRI

    Phoenix, Arizona

  • Medical Investigations, Inc.

    Little Rock, Arkansas

  • John Muir Physicians Network

    Concord, California

  • Headlands Research California, LLC

    Escondido, California

  • Scripps Whittier Diabetes Inst

    La Jolla, California

  • Clinical Trials Research_Sacramento

    Lincoln, California

  • Torrance Clin Res Inst, Inc.

    Lomita, California

  • Pacific Clinical Studies

    Los Alamitos, California

  • Downtown LA Res Ctr. Inc.

    Los Angeles, California

  • Velocity Clin Res Los Angeles

    Los Angeles, California

  • Valley Clinical Trials, Inc.

    Northridge, California

  • Clinical Trials Research_Sacramento_0

    Sacramento, California

  • San Diego Family Care

    San Diego, California

  • NorCal Endocrinology and Internal Medicine

    San Ramon, California

  • Diablo Clinical Research, Inc.

    Walnut Creek, California

  • Creekside Endocrine Associates, PC

    Denver, Colorado

  • Clinical Res Of W Florida Inc

    Clearwater, Florida

  • Northeast Research Institute

    Fleming Island, Florida

  • University of Miami

    Miami, Florida

  • Adult Medicine of Lake County, Inc.

    Mt. Dora, Florida

  • Suncoast Clin Res Port Richey

    New Port Richey, Florida

  • Clinical Neuroscience Solution

    Orlando, Florida

  • Florida Inst For Clin Res

    Orlando, Florida

  • Metabolic Research Institute Inc

    West Palm Beach, Florida

  • Javara/Privia Med Grp GA,LLC

    Albany, Georgia

  • Emory University SOM

    Atlanta, Georgia

  • Javara Inc.

    Fayetteville, Georgia

  • Physicians Research Assoc. LLC

    Lawrenceville, Georgia

  • Endocrine Research Solutions

    Roswell, Georgia

  • East West Med Res Inst

    Honolulu, Hawaii

  • Saltzer Medical Group Research

    Nampa, Idaho

  • UnityPoint Health-Diabetes Care Center

    Peoria, Illinois

  • Endeavor Health

    Skokie, Illinois

  • Iowa Diab & Endo Res Center

    West Des Moines, Iowa

  • Cotton O'Neil Diab & Endo Ctr

    Topeka, Kansas

  • The Research Group of Lexington LLC

    Lexington, Kentucky

  • Barnum Medical Research Inc.

    Natchitoches, Louisiana

  • New Orleans Center for Clinical Research

    New Orleans, Louisiana

Showing 40 of 281 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.